INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
30/01/2026
Voltar para busca
Dado oficial do USPTO
KHPG
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
31/01/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
13/09/2017
Data de registro
13/11/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
30/05/2025
Última transação
31/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
99
Localização do titular
CN
Examinador
HETZEL, DANNEAN
Unidade examinadora
L60
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a stylized wording "KHPG".
Titulares e representantes
Titulares
Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Representantes
Jennifer Sheehan Anderson Bridge Intellectual Property Services
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicines for humans for the treatment or prevention of dermatologicalcardiovascularhematologicalbonerespiratorycentral nervous systemendocrinologicalcirculatorygastroenterologicalstomachdigestivehormonaldiabeticmuscularrheumaticimmune systemocular and metabolic diseases and disorders; medicines for humans to treat or prevent diabetescoughscoldsinfluenzaheadaches and allergic reactions; anti-infectives; anti-inflammatories; vaccines; pharmaceutical preparations used for the relief of pain and to reduce fever; pharmaceutical preparations and substances for the prevention and/or treatment of cardiovascular diseaseshemophiliametabolic diseasescancermultiple sclerosisurologic diseasessexual dysfunctionosteoporosisclimacteric diseases; pharmaceutical preparationsanticoagulants and platelet aggregation inhibitors; contraceptive preparationsanalgesicsanti-pyreticsanti-inflammatory preparationsanti-septic preparationsmedicated lip balmanesthetic spray for topical useastringentspediculicidesdecongestantsantifungal agentsanti-infective pharmaceutical preparationsantacidscold preparations in the nature of preparations for treating coldsmenstrual symptom treatment preparations and dermatologicals; vitamin and mineral supplements; calcium supplements; pharmaceutical preparationsophthalmics; pharmaceutical preparations for the treatment of ophthalmic diseases and conditions; crude drugs for the treatment of central nervous system diseaseshypertensionhyperlipidemiaschizophrenia and melancholiadigestive system diseasesdyspepsiachronic gastritischronic lithogenous cholecystitischronic cholecystitis and gall-stoneophthalmology system diseaseswet Age-related Macular Degeneration (AMD)other diseasesfeverirritabilityred eyesmouth soressore throatswollen gumsconstipationpharyngitistonsillitisgingivitisupper respiratory infection (URI)acute bronchitisdiabetes and nephropathy ; Chinese patent medicine for the treatment of central nervous system diseaseshypertensionhyperlipidemiaschizophrenia and melancholiadigestive system diseasesdyspepsiachronic gastritischronic lithogenous cholecystitischronic cholecystitis and gall-stoneophthalmology system diseaseswet Age-related Macular Degeneration (AMD)other diseasesfeverirritabilityred eyesmouth soressore throatswollen gumsconstipationpharyngitistonsillitisgingivitisupper respiratory infection (URI)acute bronchitisdiabetes and nephropathy ; biochemical medicines for the treatment of cancer; radioactive medicines for the treatment of cancer; gases for medical purposes; disinfectants; solutions for contact lenses; dietetic substances adapted for medical use; food for babies; depuratives; pesticides; disinfectant wipes impregnated with disinfecting compounds; medical wound dressings; teeth filling materials
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
C71T
CANCELLED SECTION 71
30/05/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/06/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
13/11/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/02/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/02/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
10/02/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/02/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/02/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/02/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
19/04/2019
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
21/02/2019
XXCR
GENERIC MADRID TRANSACTION CREATED
21/02/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
13/02/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
13/11/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/08/2018
PUBO
PUBLISHED FOR OPPOSITION
28/08/2018
GPNX
NOTIFICATION PROCESSED BY IB
24/08/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/08/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/08/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/08/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/07/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/07/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/07/2018
ALIE
ASSIGNED TO LIE
17/07/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/07/2018
RFNT
REFUSAL PROCESSED BY IB
27/01/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/01/2018
RFRR
REFUSAL PROCESSED BY MPU
09/01/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/12/2017
CNRT
NON-FINAL ACTION WRITTEN
18/12/2017
DOCK
ASSIGNED TO EXAMINER
16/12/2017
MAFR
APPLICATION FILING RECEIPT MAILED
12/12/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/12/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
23/11/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace KHPG ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.